Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to show increased BMD of the proximal femur (total hip BMD) after injection of rhBMP-2/CPM (either 1.0 mg/mL or 2.0 mg/mL) as an adjunct to systemic osteoporosis therapy. To assess the primary objective, BMD will be measured by dual-energy x-ray absorptiometry (DXA) every 3 months from 6 to 12 months.
Critère d'inclusion
- Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture,Subjects with decreased Bone Mineral Density (BMD) at risk for hip fractures is the medical condition being investigated